Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 7 of 7 results for amiodarone

  1. Atrial fibrillation: diagnosis and management (NG196)

    This guideline covers diagnosing and managing atrial fibrillation in adults. It includes guidance on providing the best care and treatment for people with atrial fibrillation, including assessing and managing risks of stroke and bleeding.

    NICE guideline
    Last updated
    30 June 2021
    View recommendations

    Sections for NG196

  2. Dronedarone for the treatment of non-permanent atrial fibrillation (TA197)

    Evidence-based recommendations on dronedarone (Multaq) for treating non-permanent atrial fibrillation in adults.

    Technology appraisal guidance
    Last updated
    1 December 2012
    View recommendations

    Sections for TA197

  3. Chronic heart failure in adults: diagnosis and management (NG106)

    This guideline covers diagnosing and managing chronic heart failure in people aged 18 and over. It aims to improve diagnosis and treatment to increase the length and quality of life for people with heart failure.

    NICE guideline
    Published
    12 September 2018
    View recommendations

    Sections for NG106

  4. Safe prescribing of high-risk drugs

    prescribing NG5, CG100, KTT16, QS93 for Warfarin NG5, NG106, CH180 for Amiodarone NG5, CG185, CG192, QS95 for Lithium To date, I have...

    Shared learning
    Published
    10 October 2019

  5. Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults (TA157)

    Evidence-based recommendations on dabigatran etexilate (Pradaxa) for preventing venous thromboembolism after hip or knee replacement surgery in adults.

    Technology appraisal guidance
    Published
    24 September 2008
    View recommendations

    Sections for TA157

  6. Temperature control to improve neurological outcomes after cardiac arrest (IPG782)

    Evidence-based recommendations on temperature control to improve neurological outcomes after cardiac arrest. This involves controlling a person’s body temperature while they are still unconscious after their heart has been restarted. Either their body is kept at a normal temperature of between 36.5°C and 37.5°C to prevent fever, or it is cooled to between 32.0°C and 36.0°C (therapeutic hypothermia).

    Interventional procedures guidance
    Published
    23 January 2024
    View recommendations

    Sections for IPG782

  7. Chronic heart failure in adults (QS9)

    This quality standard covers assessing, diagnosing and managing chronic heart failure in adults (aged 18 and over). It describes high-quality care in priority areas for improvement. Statements cover adults with chronic heart failure with reduced ejection fraction and adults with chronic heart failure with preserved ejection fraction, unless otherwise stated.

    Quality standard
    Last updated
    10 January 2023
    View quality statements

    Sections for QS9